Recap: Applied DNA Sciences Q1 Earnings
Portfolio Pulse from Benzinga Insights
Applied DNA Sciences (NASDAQ:APDN) reported Q1 earnings with an EPS of $-0.09, beating estimates by 70.97% against an expected $-0.31. However, revenue decreased by $4.37 million from the same period last year. Despite beating EPS estimates last quarter, APDN's share price dropped by 18.43% the following day. Historical performance shows fluctuating EPS and revenue figures over the past quarters.
February 08, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Applied DNA Sciences reported a significant beat on Q1 earnings estimates but saw a decrease in revenue compared to the same period last year.
While APDN's beat on earnings estimates is positive, the decrease in revenue and historical share price drop post-earnings report suggest a mixed short-term impact. Investors may react positively to the earnings beat, but concerns over revenue decline and past share price volatility post-earnings could temper gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100